Andrew L. MacKinnon

2.4k total citations · 1 hit paper
16 papers, 1.4k citations indexed

About

Andrew L. MacKinnon is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Andrew L. MacKinnon has authored 16 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Andrew L. MacKinnon's work include Cancer, Hypoxia, and Metabolism (7 papers), Cancer Research and Treatments (4 papers) and Ubiquitin and proteasome pathways (3 papers). Andrew L. MacKinnon is often cited by papers focused on Cancer, Hypoxia, and Metabolism (7 papers), Cancer Research and Treatments (4 papers) and Ubiquitin and proteasome pathways (3 papers). Andrew L. MacKinnon collaborates with scholars based in United States. Andrew L. MacKinnon's co-authors include Jack Taunton, Francesco Parlati, Ramanujan S. Hegde, Mark K. Bennett, Mirna L.M. Rodriguez, Julie Janes, Timothy F. Stanton, Guy J. Laidig, Tania Chernov-Rogan and Eric B. Sjogren and has published in prestigious journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Andrew L. MacKinnon

16 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

2014 797 citations Matt I. Gross, Susan D. Demo et al. Molecular Cancer Therapeutics profile →

Peers

Countries citing papers authored by Andrew L. MacKinnon

Since Specialization

Citations

This map shows the geographic impact of Andrew L. MacKinnon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew L. MacKinnon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew L. MacKinnon more than expected).

Fields of papers citing papers by Andrew L. MacKinnon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew L. MacKinnon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew L. MacKinnon. The network helps show where Andrew L. MacKinnon may publish in the future.

Co-authorship network of co-authors of Andrew L. MacKinnon

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew L. MacKinnon. A scholar is included among the top collaborators of Andrew L. MacKinnon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew L. MacKinnon. Andrew L. MacKinnon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Abstract 1816: Identification of novel VPS4A inhibitors for the treatment of VPS4B-deleted cancers 2022 ·Cancer Research ·(unknown), Jason Chen, Sacha J. Holland, (unknown), (unknown), Francesco Parlati, (unknown), Eric B. Sjogren, (unknown), Susanne Steggerda, Andrew L. MacKinnon	1
2	The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma 2021 ·PLoS ONE ·Ethan Emberley, Alison Pan, Jason Chen, (unknown), Matt Gross, Tony Chieh‐Ting Huang, Weiqun Li, Andrew L. MacKinnon, (unknown), (unknown), Susanne Steggerda, Tracy Wang, Francesco Parlati	33
3	The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies 2020 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Leila J. Williams, (unknown), Courtney W. Hudgens, Grant M. Fischer, (unknown), Barbara Knighton, Lin Tan, Philip L. Lorenzi, Andrew L. MacKinnon, Jennifer L. McQuade, Yared Hailemichael, Jason Roszik, Weiyi Peng, Y.N. Vashisht Gopal	112
4	705 Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) 2020 ·SHILAP Revista de lepidopterología ·Andrew L. MacKinnon, (unknown), Jason Chen, Tony Chieh‐Ting Huang, Weiqun Li, Yong Ma, (unknown), Susanne Steggerda, Winter Zhang, Francesco Parlati	6
5	Discovery of an Inhibitor of the Proteasome Subunit Rpn11 2017 ·Journal of Medicinal Chemistry ·Christian Perez, Jing Li, Francesco Parlati, (unknown), Yuyong Ma, Andrew L. MacKinnon, Tsui‐Fen Chou, Raymond J. Deshaies, Seth M. Cohen	64
6	CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors 2016 ·European Journal of Cancer ·Ethan Emberley, Mark K. Bennett, (unknown), Matt Gross, Tony Chieh‐Ting Huang, (unknown), Andrew L. MacKinnon, Alison Pan, Marianne Rodriguez, Susanne Steggerda, (unknown), (unknown), (unknown), (unknown)	6
7	Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma 2015 ·Blood ·Andrew L. MacKinnon, Mark K. Bennett, Matt Gross, Julie Janes, Weiqin Li, (unknown), Tracy Wang, Winter Zhang, Francesco Parlati	4
8	Abstract 4711: CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity 2015 ·Cancer Research ·Mirna L.M. Rodriguez, Winter Zhang, Mark K. Bennett, Ethan Emberley, (unknown), Julie Janes, Andrew L. MacKinnon, Alison Pan, Susanne Steggerda, Melissa Works, Francesco Parlati	4
9	Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer breakdown → 2014 ·Molecular Cancer Therapeutics ·Matt I. Gross, Susan D. Demo, Jennifer B. Dennison, Lijing Chen, Tania Chernov-Rogan, Bindu Goyal, Julie Janes, Guy J. Laidig, Evan R. Lewis, Jun Li, Andrew L. MacKinnon, Francesco Parlati, Mirna L.M. Rodriguez, Peter J. Shwonek, Eric B. Sjogren, Timothy F. Stanton, Taotao Wang, Jinfu Yang, Frances Zhao, Mark K. Bennett	797
10	Biomarkers of Response to the Glutaminase Inhibitor CB-839 in Multiple Myeloma Cells 2014 ·Blood ·Andrew L. MacKinnon, Mark K. Bennett, Mirna L.M. Rodriguez, Francesco Parlati	2
11	An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gate 2014 ·eLife ·Andrew L. MacKinnon, Ville O. Paavilainen, Ajay Sharma, Ramanujan S. Hegde, Jack Taunton	63
12	Secretory Protein Profiling Reveals TNF-α Inactivation by Selective and Promiscuous Sec61 Modulators 2011 ·Chemistry & Biology ·(unknown), Andrew L. MacKinnon, Jennifer L. Garrison, Ajay Sharma, Eric J. Kunkel, Ramanujan S. Hegde, Jack Taunton	39
13	Target Identification by Diazirine Photo‐Cross‐Linking and Click Chemistry 2009 ·PubMed ·Andrew L. MacKinnon, Jack Taunton	93
14	Asymmetric synthesis of a highly soluble ‘trimeric’ analogue of the chiral nematic liquid crystal twist agent Merck S1011 2009 ·Liquid Crystals ·James A. Rego, (unknown), Andrew L. MacKinnon, (unknown)	16
15	Photo-Leucine Incorporation Reveals the Target of a Cyclodepsipeptide Inhibitor of Cotranslational Translocation 2007 ·Journal of the American Chemical Society ·Andrew L. MacKinnon, Jennifer L. Garrison, Ramanujan S. Hegde, Jack Taunton	111
16	Half-of-Sites Binding of Orotidine 5‘-Phosphate and α-d-5-Phosphorylribose 1-Diphosphate to Orotate Phosphoribosyltransferase from Saccharomyces cerevisiae Supports a Novel Variant of the Theorell−Chance Mechanism with Alternating Site Catalysis 2006 ·Biochemistry ·Ronald W. McClard, (unknown), Andrew L. MacKinnon, (unknown)	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact